Actively Recruiting
Clinical and Metabolomics Studies on the Improvement of Ovarian Reserve by Acupoint Photodynamic Therapy and Traditional Chinese Medicine Treatment
Led by Peking Union Medical College Hospital · Updated on 2026-01-29
90
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Diminished Ovarian Reserve (DOR) refers to a reduction in the number of recruitable follicles in the ovaries and/or a decline in oocyte quality. Current research on its etiology and treatment remains unsatisfactory. This study will be conducted as a single-center, prospective, parallel, randomized, controlled clinical trial in DOR patients. Eligible subjects will be randomly assigned to three groups: LLLT (acupoint photodynamic therapy) + placebo (Dingkun Dan Simulant), LLLT (acupoint photodynamic therapy) + Chinese medicine (Dingkun Dan), and Chinese medicine (Dingkun Dan) alone. Clinical data and serum metabolomics will be assessed at baseline and after the 3-month treatment.
CONDITIONS
Official Title
Clinical and Metabolomics Studies on the Improvement of Ovarian Reserve by Acupoint Photodynamic Therapy and Traditional Chinese Medicine Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 25 to 40 years
- Diagnosed with diminished ovarian reserve by at least two criteria: Basal FSH 10-25 IU/L, AMH < 1.1 ng/mL, or antral follicle count < 7
- Meet diagnostic criteria for kidney deficiency syndrome in traditional Chinese medicine
- Voluntarily agree to participate and provide written informed consent
You will not qualify if you...
- Presence of organic lesions such as ovarian tumors, pituitary adenomas, endometrial tuberculosis, intrauterine adhesions, or endometrial damage after abortion
- Diagnosis of polycystic ovary syndrome, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, or thyroid dysfunction
- Use of sex hormones for infertility within the past 3 months
- Serious or unstable diseases affecting liver, kidney, gastrointestinal, cardiovascular, respiratory, endocrine, neurological, immune, hematological, or psychiatric systems
- History of substance abuse or dependence in the past 3 months
- Heavy smoking (20 or more cigarettes per day)
- Allergy to the investigational drug or photosensitivity, or contraindications to Dingkun Dan
- Participation in another investigational drug trial within 1 month before this study
- Other conditions that may reduce enrollment likelihood or cause loss to follow-up, such as frequent job changes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking union medical college hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
Y
Yingying Guo, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here